Market-Moving News for October 23rd
Portfolio Pulse from ryanfaloona@benzinga.com
LumiraDx (LMDX) partners with AstraZeneca and Everton in the Community to set up England's first heart and lung screening hub, causing its stock to surge by 387%. Apollomics (APLM) announces 75% overall response rate in NSCLC patients with MetEx14 Skipping Mutation from Vebreltinib, leading to a 34% increase in its stock. Arvinas (ARVN) reports positive interim data from second generation ARV-766 in mCRPC, reinforcing the potential of its PROTAC® AR Degraders and causing a 9% rise in its stock.
October 23, 2023 | 12:56 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Apollomics announced a 75% overall response rate in NSCLC patients with MetEx14 Skipping Mutation from Vebreltinib, leading to a 34% increase in its stock.
The announcement of a 75% overall response rate in NSCLC patients from Vebreltinib is a positive development for Apollomics, which is reflected in the increase in its stock.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100
POSITIVE IMPACT
Arvinas reported positive interim data from second generation ARV-766 in mCRPC, reinforcing the potential of its PROTAC® AR Degraders and causing a 9% rise in its stock.
The positive interim data from second generation ARV-766 in mCRPC is a positive development for Arvinas, which is reflected in the rise in its stock.
CONFIDENCE 90
IMPORTANCE 60
RELEVANCE 100
POSITIVE IMPACT
LumiraDx's partnership with AstraZeneca and Everton in the Community for a heart and lung screening hub led to a 387% surge in its stock.
The partnership with AstraZeneca and Everton in the Community for a heart and lung screening hub is a significant development for LumiraDx, which is reflected in the sharp rise in its stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100